Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
BJ's Restaurants, Inc. (NASDAQ: BJRI) shares increased 21.55 percent to close at $33.62 a share Thursday. The stock traded between $29.70 and $34.17 on volume of 3.69 million shares traded. Analysts at Buckingham Research have recently upgraded the company’s rating to “buy” from “neutral”. Shares of BJ's Restaurants have gained approximately 8.0 percent year-to-date.
Find out more about BJ's Restaurants including full access to the free equity report at:
Durata Therapeutics Inc. (NASDAQ: DRTX) shares gained 1.36 percent to close at $14.18 a share Thursday. The stock traded between $13.77 and $14.80 on volume of 581,817 shares traded. Analysts at Roth Capital have recently initiated coverage on the company with a “buy” rating and a price target of $20.00. Shares of Durata Therapeutics have gained approximately 10.0 percent year-to-date.
Find out more about Durata Therapeutics including full access to the free equity report at:
Quantum Corp. (NYSE: QTM) shares increased 3.54 percent to close at $1.17 a share Thursday. The stock traded between $1.14 and $1.18 on volume of 1.49 million shares traded. Analysts at Northland Securities have recently reinstated coverage on the company with a “market perform” rating and a price target of $1.50. Shares of Quantum have fallen approximately 2.5 percent year-to-date.
Find out more about Quantum including full access to the free equity report at:
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares gained 0.04 percent to close at $49.82 a share Thursday. The stock traded between $49.77 and $51.41 on volume of 9.56 million shares traded. Analysts at Leerink have recently upgraded the company’s rating to “outperform” from “market perform”. Shares of Teva Pharmaceutical have gained approximately 24.0 percent year-to-date.
Find out more about Teva Pharmaceutical including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing